|
Valoración DCF de Logicbio Therapeutics, Inc. (LOGC)
US | Consumer Cyclical | Specialty Retail | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
LogicBio Therapeutics, Inc. (LOGC) Bundle
¡Maximice la eficiencia y mejore la precisión con nuestra calculadora DCF (logC)! Utilizando los datos de la Terapia Logicbio Real y los supuestos personalizables, esta herramienta le permite pronosticar, analizar y evaluar (LOGC) al igual que un inversor experimentado.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | 2,541.0 | 2,085.0 | 571.0 | 287.0 | 186.3 | 121.0 | 78.5 | 51.0 | 33.1 |
| Revenue Growth, % | 0 | 0 | -17.95 | -72.61 | -49.74 | -35.07 | -35.07 | -35.07 | -35.07 | -35.07 |
| EBITDA | -134.0 | -619.0 | -358.0 | -392.0 | -324.0 | -41.1 | -26.7 | -17.3 | -11.2 | -7.3 |
| EBITDA, % | 100 | -24.36 | -17.17 | -68.65 | -112.89 | -22.04 | -22.04 | -22.04 | -22.04 | -22.04 |
| Depreciation | .3 | 12.0 | 9.0 | 6.0 | 4.0 | 38.5 | 25.0 | 16.2 | 10.5 | 6.8 |
| Depreciation, % | 100 | 0.47226 | 0.43165 | 1.05 | 1.39 | 20.67 | 20.67 | 20.67 | 20.67 | 20.67 |
| EBIT | -134.3 | -631.0 | -367.0 | -398.0 | -328.0 | -41.8 | -27.1 | -17.6 | -11.4 | -7.4 |
| EBIT, % | 100 | -24.83 | -17.6 | -69.7 | -114.29 | -22.43 | -22.43 | -22.43 | -22.43 | -22.43 |
| Total Cash | 50.6 | 2,129.0 | 1,159.0 | 719.0 | 382.0 | 163.7 | 106.3 | 69.0 | 44.8 | 29.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 95.0 | 83.0 | 17.0 | 14.0 | 7.0 | 40.6 | 26.4 | 17.1 | 11.1 | 7.2 |
| Account Receivables, % | 100 | 3.27 | 0.81535 | 2.45 | 2.44 | 21.79 | 21.79 | 21.79 | 21.79 | 21.79 |
| Inventories | .0 | .0 | .0 | .0 | .0 | 37.3 | 24.2 | 15.7 | 10.2 | 6.6 |
| Inventories, % | 100 | 0 | 0 | 0 | 0 | 20 | 20 | 20 | 20 | 20 |
| Accounts Payable | 171.0 | 434.0 | 67.0 | 53.0 | 30.0 | 52.2 | 33.9 | 22.0 | 14.3 | 9.3 |
| Accounts Payable, % | 100 | 17.08 | 3.21 | 9.28 | 10.45 | 28.01 | 28.01 | 28.01 | 28.01 | 28.01 |
| Capital Expenditure | -1.4 | -2.0 | -2.0 | -2.0 | -3.0 | -.6 | -.4 | -.2 | -.2 | -.1 |
| Capital Expenditure, % | 100 | -0.07870917 | -0.09592326 | -0.35026 | -1.05 | -0.31404 | -0.31404 | -0.31404 | -0.31404 | -0.31404 |
| Tax Rate, % | -1.6 | -1.6 | -1.6 | -1.6 | -1.6 | -1.6 | -1.6 | -1.6 | -1.6 | -1.6 |
| EBITAT | -134.4 | -632.7 | -377.5 | -399.0 | -333.3 | -41.8 | -27.1 | -17.6 | -11.4 | -7.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -59.5 | -347.7 | -671.5 | -406.0 | -348.3 | -52.6 | 6.5 | 4.2 | 2.7 | 1.8 |
| WACC, % | 13.81 | 13.81 | 13.81 | 13.81 | 13.81 | 13.81 | 13.81 | 13.81 | 13.81 | 13.81 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -35.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 2 | |||||||||
| Terminal Value | 15 | |||||||||
| Present Terminal Value | 8 | |||||||||
| Enterprise Value | -28 | |||||||||
| Net Debt | -232 | |||||||||
| Equity Value | 204 | |||||||||
| Diluted Shares Outstanding, MM | 24 | |||||||||
| Equity Value Per Share | 8.61 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled financial data for LogicBio Therapeutics, Inc. (LOGC).
- Real-World Data: Access to historical data and forward-looking estimates (highlighted in the yellow cells).
- Forecast Flexibility: Adjust key forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Quickly observe how your inputs affect the valuation of LogicBio Therapeutics, Inc. (LOGC).
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive Data: LogicBio’s historical financials and projected forecasts are readily available.
- Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Observe LogicBio’s intrinsic value update instantly.
- Intuitive Visualizations: Dashboard graphs illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool tailored for analysts, investors, and financial professionals.
How It Works
- 1. Access the Template: Download and open the Excel file containing LogicBio Therapeutics, Inc.'s preloaded data.
- 2. Modify Assumptions: Adjust key parameters such as growth rates, WACC, and capital expenditures.
- 3. Analyze Results Instantly: The DCF model automatically computes intrinsic value and NPV.
- 4. Explore Scenarios: Evaluate various forecasts to understand different valuation outcomes.
- 5. Present with Assurance: Share professional valuation insights to back your strategic decisions.
Why Choose This Calculator for LogicBio Therapeutics, Inc. (LOGC)?
- User-Friendly Interface: Perfectly crafted for both novices and seasoned professionals.
- Customizable Parameters: Easily adjust inputs to suit your specific analysis needs.
- Real-Time Adjustments: Observe immediate updates to LogicBio's valuation as you change inputs.
- Preloaded Data: Comes equipped with LogicBio's current financial information for swift evaluations.
- Preferred by Experts: Utilized by investors and analysts for making well-informed choices.
Who Should Use LogicBio Therapeutics, Inc. (LOGC)?
- Investors: Gain insights into the potential of gene therapy investments with our comprehensive analysis tools.
- Biotech Analysts: Streamline your research with pre-built models tailored for evaluating biotech companies.
- Healthcare Consultants: Easily modify reports and presentations to showcase the impact of LogicBio's innovations.
- Life Sciences Enthusiasts: Enhance your knowledge of genetic medicine and its market implications through detailed case studies.
- Academics and Students: Utilize our resources as a hands-on learning tool in biotechnology and pharmacology courses.
What the Template Contains
- Pre-Filled Data: Includes LogicBio Therapeutics’ historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze LogicBio Therapeutics’ profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.